Search Results - "HUGHES, Brett G. M"

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non―Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib by PUNNOOSE, Elizabeth A, ATWAL, Siminder, LACKNER, Mark R, WEIQUN LIU, RAJA, Rajiv, FINE, Bernard M, HUGHES, Brett G. M, HICKS, Rodney J, HAMPTON, Garret M, AMLER, Lukas C, PIRZKALL, Andrea

“…Elevated levels or increases in circulating tumor cells (CTC) portend poor prognosis in patients with epithelial cancers. Less is known about CTCs as surrogate…”
Get full text

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study by Cho, Byoung Chul, Braña, Irene, Cirauqui, Beatriz, Aksoy, Sercan, Couture, Felix, Hong, Ruey-Long, Miller, Jr, Wilson H, Chaves-Conde, Manuel, Teixeira, Margarida, Leopold, Lance, Munteanu, Mihaela, Ge, Joy Yang, Swaby, Ramona F, Hughes, Brett G M

“…Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, and new treatment options are needed. Combining immunotherapies with differing…”
Get full text

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN) by Ahern, Elizabeth, Cubitt, Annette, Ballard, Emma, Teng, Michele W L, Dougall, William C, Smyth, Mark J, Godbolt, David, Naidoo, Rishendran, Goldrick, Amanda, Hughes, Brett G M

“…Neoadjuvant immunotherapy targeting immune checkpoint programmed death-1 (PD-1) is under investigation in various tumour settings including non-small-cell lung…”
Get full text

Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629) by Grob, Jean-Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M, Bauman, Jessica R, Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F, Hughes, Brett G M

“…Treatment options are limited for patients with recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 70% in…”
Get full text

Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients by Zhang, Xi, Weeramange, Chameera Ekanayake, Hughes, Brett G. M., Vasani, Sarju, Liu, Zhen Yu, Warkiani, Majid, Hartel, Gunter, Ladwa, Rahul, Thiery, Jean Paul, Kenny, Liz, Breik, Omar, Punyadeera, Chamindie

“…Patients with head and neck squamous cell carcinoma (HNSCC) are at a high risk of developing recurrence and secondary cancers. This study evaluates the…”
Get full text

The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review by Edwards, Anna, Brown, Teresa, Hughes, Brett G. M., Bauer, Judy

“…Purpose Human papillomavirus (HPV) is now the primary cause of oropharyngeal head and neck cancer (OPC) worldwide; yet limited research has examined the effect…”
Get full text

Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia by Ngo, Preston, Karikios, Deme, Goldsbury, David, Wade, Stephen, Lwin, Zarnie, Hughes, Brett G. M., Fong, Kwun M., Canfell, Karen, Weber, Marianne

“…Background and Objective Since 2016, new therapies have transformed the standard of care for lung cancer, creating a need for up-to-date evidence for health…”
Get full text

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time? by Ahern, Elizabeth, Solomon, Ben J, Hui, Rina, Pavlakis, Nick, O'Byrne, Ken, Hughes, Brett G M

“…Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves surgery in combination with postoperative (adjuvant) platinum-based…”
Get full text

Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients by Kulasinghe, Arutha, Taheri, Touraj, O'Byrne, Ken, Hughes, Brett G M, Kenny, Liz, Punyadeera, Chamindie

“…Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify…”
Get full text

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells by Braun, Matthias, Aguilera, Amelia Roman, Sundarrajan, Ashmitha, Corvino, Dillon, Stannard, Kimberley, Krumeich, Sophie, Das, Indrajit, Lima, Luize G., Meza Guzman, Lizeth G., Li, Kunlun, Li, Rui, Salim, Nazhifah, Jorge, Maria Villancanas, Ham, Sunyoung, Kelly, Gabrielle, Vari, Frank, Lepletier, Ailin, Raghavendra, Ashwini, Pearson, Sally, Madore, Jason, Jacquelin, Sebastien, Effern, Maike, Quine, Brodie, Koufariotis, Lambros T., Casey, Mika, Nakamura, Kyohei, Seo, Eun Y., Hölzel, Michael, Geyer, Matthias, Kristiansen, Glen, Taheri, Touraj, Ahern, Elizabeth, Hughes, Brett G.M., Wilmott, James S., Long, Georgina V., Scolyer, Richard A., Batstone, Martin D., Landsberg, Jennifer, Dietrich, Dimo, Pop, Oltin T., Flatz, Lukas, Dougall, William C., Veillette, André, Nicholson, Sandra E., Möller, Andreas, Johnston, Robert J., Martinet, Ludovic, Smyth, Mark J., Bald, Tobias

“…The activating receptor CD226 is expressed on lymphocytes, monocytes, and platelets and promotes anti-tumor immunity in pre-clinical models. Here, we examined…”
Get full text

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing by Rischin, Danny, Migden, Michael R, Lim, Annette M, Schmults, Chrysalyne D, Khushalani, Nikhil I, Hughes, Brett G M, Schadendorf, Dirk, Dunn, Lara A, Hernandez-Aya, Leonel, Chang, Anne Lynn S, Modi, Badri, Hauschild, Axel, Ulrich, Claas, Eigentler, Thomas, Stein, Brian, Pavlick, Anna C, Geiger, Jessica L, Gutzmer, Ralf, Alam, Murad, Okoye, Emmanuel, Mathias, Melissa, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Lowy, Israel, Fury, Matthew G, Guminski, Alexander

“…BackgroundCemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase…”
Get full text

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412 by Machiels, Jean-Pascal, Tao, Yungan, Burtness, Barbara, Tahara, Makoto, Licitra, Lisa, Rischin, Danny, Waldron, John, Simon, Christian, Gregoire, Vincent, Harrington, Kevin, Alves, Gustavo Vasconcelos, Figueiredo Lima, Iane Pinto, Pointreau, Yoann, M Hughes, Brett G, Aksoy, Sercan, Hetnal, Marcin, Ge, Joy Y, Brown, Holly, Cheng, Jonathan, Bidadi, Behzad, Siu, Lillian L

“…Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including…”
Get full text

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy by Sadeghirad, Habib, Liu, Ning, Monkman, James, Ma, Ning, Cheikh, Bassem Ben, Jhaveri, Niyati, Tan, Chin Wee, Warkiani, Majid Ebrahimi, Adams, Mark N, Nguyen, Quan, Ladwa, Rahul, Braubach, Oliver, O'Byrne, Ken, Davis, Melissa, Hughes, Brett G M, Kulasinghe, Arutha

“…Mucosal head and neck squamous cell carcinoma (HNSCC) are the seventh most common cancer, with approximately 50% of patients living beyond 5 years. Immune…”
Get full text

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis by Rischin, Danny, Khushalani, Nikhil I, Schmults, Chrysalyne D, Guminski, Alexander, Chang, Anne Lynn S, Lewis, Karl D, Lim, Annette M, Hernandez-Aya, Leonel, Hughes, Brett G M, Schadendorf, Dirk, Hauschild, Axel, Thai, Alesha A, Stankevich, Elizabeth, Booth, Jocelyn, Yoo, Suk-Young, Li, Siyu, Chen, Zhen, Okoye, Emmanuel, Chen, Chieh-I, Mastey, Vera, Sasane, Medha, Lowy, Israel, Fury, Matthew G, Migden, Michael R

“…BackgroundTo provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma…”
Get full text

Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin by Nottage, Michelle K., Lin, Charles, Hughes, Brett G. M., Kenny, Lizbeth, Smith, David D., Houston, Kathleen, Francesconi, Alessandra

“…ABSTRACT Background The purpose of this study was to present our evaluation of the outcomes of concurrent chemoradiotherapy (CRT) in patients with locally…”
Get full text

Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas by Sadeghirad, Habib, Monkman, James, Mehdi, Ahmed M, Ladwa, Rahul, O'Byrne, Ken, Hughes, Brett G M, Kulasinghe, Arutha

“…Head and neck squamous cell carcinoma (HNSCC) often presents with locoregional or distant disease, despite multimodal therapeutic approaches, which include…”
Get full text

An Occult HPV-Driven Oropharyngeal Squamous Cell Carcinoma Discovered Through a Saliva Test by Tang, Kai Dun, Vasani, Sarju, Taheri, Touraj, Walsh, Laurence J, Hughes, Brett G M, Kenny, Lizbeth, Punyadeera, Chamindie

“…Oropharyngeal cancer (OPC) caused by human papillomavirus (HPV) is a rising global concern. Early lesions are small and are often located in difficult to…”
Get full text

Application of circulating tumour cells to predict response to treatment in head and neck cancer by Zhang, Xi, Ekanayake Weeramange, Chameera, Hughes, Brett G. M., Vasani, Sarju, Liu, Zhen Yu, Warkiani, Majid Ebrahimi, Hartel, Gunter, Ladwa, Rahul, Thiery, Jean Paul, Kenny, Liz, Punyadeera, Chamindie

“…Background Local recurrence and metastasis remain the major causes of death in head and neck cancer (HNC) patients. Circulating tumour cells (CTCs) are shed…”
Get full text

Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC by Moroney, Laura B., Ward, Elizabeth C., Helios, Jennifer, Crombie, Jane, Burns, Clare L., Blake, Claire, Comans, Tracy, Chua, Benjamin, Kenny, Lizbeth, Hughes, Brett G. M.

“…Purpose There are no evidence-based guidelines informing which patients with head and neck cancer (HNC) require regular speech pathology (SP) support during…”
Get full text

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer by Miller, Richard A, Luke, Jason John, Hu, Shenshen, Mahabhashyam, Suresh, Jones, William B, Marron, Thomas, Merchan, Jaime R, Hughes, Brett G M, Willingham, Stephen B

“…BackgroundCD73 is widely expressed on immune cells playing a critical role in immunomodulatory functions including cell adhesion and migration, as a…”
Get full text